Nachrichten und Videos - KINIKSA PHARMACEUTICALS

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the event will also be available on Kiniksa’s website...

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the event will also be available on...

– ARCALYST ® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 – – Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) --...

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via telephone may...

– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart development in Sjogren’s Disease fully funded through Phase 3 – – Company expects to remain cash flow positive on an annual basis within current operating plan – HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage...

– ARCALYST ® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint – – Abiprubart Phase 2 rheumatoid arthritis data from Cohort 4 and a new development indication expected in April 2024 – – Cash reserves of $206.4 million expected to fund operations into at least 2027 – – Conference call and...

HAMILTON, Bermuda, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, February 28, 2024 at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2023 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via...

– ARCALYST ® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level – – Abiprubart Phase 2 rheumatoid arthritis data from Cohort 4 expected in Q2 2024 – – Cash reserves of $206.3 million (unaudited) expected to fund operations into at...

HAMILTON, Bermuda, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the webcast will also be available on Kiniksa’s website within...

– ARCALYST ® (rilonacept) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth – – KPL-404 Phase 2 rheumatoid arthritis data from Cohorts 1-3 now expected in Q1 2024 – – Cash reserves of $201 million expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company...

HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8:30 a.m. Eastern Time to report its third quarter 2023 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via telephone may...

– ARCALYST ® (rilonacept) Q2 2023 net product revenue of $54.5 million – – ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint – – KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024 – – Cash reserves now expected to fund operations into at least 2027 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, July 25, 2023 (GLOBE NEWSWIRE) -- Kiniksa...

HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via telephone may...

HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. Pacific Time (11:40 a.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the event will also be available...

– ARCALYST ® (rilonacept) Q1 2023 net product revenue of $42.7 million – – ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint – – Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling patients; data expected in 1H 2024 – – Cash reserves now expected to fund operations into at least 2026 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON,...

HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via telephone may register...

– ARCALYST ® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - $205 million, representing >60% year-over-year growth at the midpoint – – ARCALYST average total duration of therapy as of the end of Q4 2022 was ~18 months after accounting for patient restarts – – Cash reserves expected to fund operations into at least 2025 – HAMILTON, Bermuda, Feb. 28,...

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . Individuals interested in participating in the call via...

HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the webcast will also be available on Kiniksa’s website within...

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com . A replay of the webcast will also be available on...